|
Pacira Pharmaceuticals lets injections last longer with its DepoFoam technology. The company develops sustained-release therapies based on DepoFoam, an injectable drug delivery technology that allows both immediate and sustained release. Its two marketable products are DepoCyt for treating cancer-related neoplastic meningitis and DepoDur for the treatment of post-operative pain. Pacira's lead candidate is EXPAREL, an injectable local anesthetic. The company has two manufacturing facilities that make its Depo products. Once the injectables subsidiary of drug-delivery company SkyePharma PLC, Pacira was bought out in 2007 by an investor group led by MPM Capital, OrbiMed, HBM Bioventures, and Sanderling Ventures.
|
| | | Contact Information | |
Address: |
10450 Science Center Dr.
San Diego, CA 92121
| | Phone: | 858-625-2414 | | Fax: | 858-678-3999 |
|
| Financial
Highlights | | Fiscal Year End: | December |
|
|
Key People
| | • |
Chairman:
Frederick A. (Fred) Middleton
| | • |
President, CEO, and Director:
David M. (Dave) Stack
| | • |
COO:
Ken Cunningham
|
|
|
